Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo- and Positive−Controlled, 4-Period Crossover Thorough QT Study to Evaluate the Effect of a Single Dose of TD-4208 on Cardiac Repolarization in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2021
Price :
$35
*
At a glance
- Drugs Revefenacin (Primary) ; Moxifloxacin
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Mylan Pharmaceuticals Inc.; Theravance Biopharma
- 11 Oct 2018 According to a Theravance Biopharma media release, data from this study were presented at the 2018 CHEST annual meeting.
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society.
- 02 Aug 2016 Status changed from active, no longer recruiting to completed.